Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.

van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators. · 2017

Read Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. by van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5642327.txt.

Introduction

van Veldhuisen and co-authors report a randomized trial in Circulation. The trial is called EFFECT-HF. It tested intravenous ferric carboxymaltose in chronic heart failure. All patients also had iron deficiency. The treatment ran for 24 weeks against standard care. In total, 174 patients enrolled at 28 sites in nine countries. The main outcome was change in peak oxygen uptake.

Iron stores rose clearly in the treated group. Peak oxygen uptake stayed near flat with treatment. It fell in the standard care group. The gap was 1.04 units and met statistical significance. Without imputing deaths, that gap lost significance. Treated patients also reported better function and quality of life. No deaths occurred in the treated group during the study.

Catalog record

CREATORvan Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5642327

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency By Dirk J. van Veldhuisen, Piotr Ponikowski, Peter van der Meer, Marco Metra, Michael Böhm, Artem Doletsky, Adriaan A. Voors, Iain C. Macdougall, Stefan D. Anker, Bernard Roubert, Lorraine Zakin, Alain Cohen-Solal Published in: Circulation DOI: 10.1161/CIRCULATIONAHA.117.027497 ABSTRACT Supplemental Digital Content is available in the text. Editorial, see p 1384 Clinical PerspectiveWhat Is New?Iron deficiency is increasingly recognized as a serious comorbidity in patients with heart failure and is associated with increased morbidity and mortality.In earlier studies, patient treatment with ferric carboxymaltose maltose (FCM, intravenous iron) was shown to decrease symptoms and improve functional capacity.In the present study, iron supplementation with FCM led to repletion of iron stores and improvement in measures of disease severity and quality of life.A decline in peak VO2 in the control group was driven by deaths, with imputed values of 0 in the control group. This decline was not seen in the FCM group.What Are the Clinical Implications?Iron supplementation with (intravenous) FCM significantly increased serum ferritin and transferrin saturation.The effects of iron supplementation with (intravenous) FCM include improvements in quality of life.Further study is needed to determine the impact of intravenous FCM supplementation on functional capacity and clinical outcome. Iron deficiency is increasingly recognized as an important comorbidity in patients with heart failure (HF) and is present in up to 35% to 50% of patients with HF.1–5 Its prevalence is related to the severity of the disease and is a strong and independent predictor of outcome, in both the presence and absence of anemia. Iron deficiency decreases exercise capacity, in both healthy volunteers and patients with chronic HF.4,6–8 Iron plays an important role in oxygen transport, not only through hematopoiesis but also in the metabolism of cardiac and skeletal muscles. All these factors play a role in the reduced exercise capacity in HF. Given the importance of iron deficiency, a clear rationale exists for investigating the effect of correcting this, and a few small studies suggested cause for optimism.2,7 More recently, 2 larger randomized controlled trials have been conducted with (intravenous) iron (ie, ferric carboxymaltose [FCM]) in patients with HF with iron deficiency.9,10 These studies showed that FCM improved symptoms, quality of life, and functional capacity, irrespective of the presence of anemia. The drug was well tolerated and safe. At 1-year follow-up, FCM was also associated with a reduction in the risk of first hospitalization for worsening HF.10 Exercise intolerance is one of the hallmarks of chronic HF, and it is further reduced in the presence of iron deficiency.2,4,6–8 Although intravenous iron (FCM) was shown to increase 6-minute walking test distance in patients with HF,9,10 this parameter may be subject to some bias. Therefore, investigation of more robust and objective parameters during cardiopulmonary exercise testing (CPET), such as peak oxygen consumption (peak VO2),11 would seem useful. The aim of the present EFFECT-HF study (Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure) was to examine the effect of treatment with intravenous FCM, compared with standard of care, on exercise capacity in patients with symptomatic chronic HF and iron deficiency. METHODS Patient Population Patients were eligible for the EFFECT-HF study if they were ≥18 years of age, had clinically stable mild to moderate chronic HF (New York Heart Association [NYHA] functional class II–III), and were on optimal background therapy for HF for ≥4 weeks and with no dose changes in the last 2 weeks. Their left ventricular ejection fraction had to be ≤45% and had to be performed in ≤3 months of screening and >3 months after stable β-blocker therapy or device implantation, in particular cardiac resynchronization therapy. Plasma brain natriuretic peptide (BNP) concentration at baseline had to be >100 pg/mL or N-terminal (NT) proBNP had to be >400 pg/mL. Patients were required to have a decreased exercise capacity, as shown by a reproducible peak VO2 of 10 to 20 mL/kg/min. Patients also needed to have documented iron deficiency, as defined by a serum ferritin <100 ng/mL or a serum ferritin of 100 to 300 ng/mL in combination with a transferrin saturation (TSAT) <20%. Patients were excluded from the study if they had a known sensitivity to FCM, a history of iron overload, or received erythropoiesis-stimulating agents, intravenous iron therapy and/or blood transfusions in the 6 weeks before randomization. There was no lower limit of hemoglobin (Hb), but subjects with an immediate need of blood transfusion or an Hb >15 g/dL were also excluded. Patients who had undergone an exercise training program in the previous 3 months, or those planned in the next 6 months, as well as those with an active bacterial infection, those with serious liver disease (transaminases >3 times the upper limit), a known vitamin B12 or serum folate deficiency, or a known human immunodeficiency virus or hepatitis B or C infection were also excluded. Patients with clinical evidence of current malignancy and on renal dialysis were also not included. Patients with unstable angina pectoris, severe valvular disease, or left ventricular outflow tract obstruction; patients with atrial fibrillation or flutter with a ventricular response rate of >100 beats per minute at rest; and patients with recent (<3 months) acute coronary syndrome, coronary artery bypass surgery, percutaneous coronary interventions, transient ischemic attack, or stroke were also excluded. Finally, women who were pregnant or without adequate contraception and subjects with (recent) participation in another study or with low body weight (<35 kg) were excluded. The study followed the principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Medical Ethics Committee of each participating center, and all subjects gave their written informed consent before enrollment. Study Design The EFFECT-HF study was a prospective randomized controlled, multicenter, open-label trial with blinded end-point evaluation. It aimed to examine the effect of treatment with intravenous FCM, compared with standard of care, on exercise capacity in patients with symptomatic chronic HF and iron deficiency. After an initial screening period (≤12 weeks), eligible subjects were randomized (1:1) to FCM or usual care for a period of 24 weeks. Study visits took place on day 0 (baseline) and at weeks 6, 12, and 24. Within the screening period, the reproducibility of peak VO2 had to be confirmed with applicable tests. Subjects randomized to standard of care could receive oral iron at the discretion of their attending physician but were not permitted intravenous iron. The primary end point was the change in peak VO2 from baseline to 24 weeks. Secondary end points included the effect of FCM on hematinic indices (Hb, ferritin, and TSAT), natriuretic peptides (BNP and NTproBNP), NYHA functional class, and patient global assessment. In addition, safety parameters were collected. The study was designed and conducted by the steering committee, and an independent data safety monitoring board reviewed data on an ongoing basis. The independent Endpoint Adjudication Committee adjudicated all hospitalizations and deaths. All analyses were performed according to a predefined statistical analysis plan validated by the sponsor, Vifor Pharma Ltd. The manuscript was prepared by the principal investigator (D.J.v.V.) and subsequently reviewed by all authors and Vifor Pharma for scientific accuracy, but the authors had final authority. The authors vouch for the accuracy

Read the complete text